Status:
COMPLETED
Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.
Lead Sponsor:
University Of Perugia
Conditions:
HIV Infection With Other Conditions
Cardiovascular Risk Factor
Eligibility:
All Genders
50-70 years
Phase:
PHASE4
Brief Summary
The investigator tested the efficacy of maraviroc intensification on down-regulating atherosclerotic progression in HIV infected patients with optimal viro-immunologic control and at high cardiovascul...
Detailed Description
Experimental CCR5 antagonism with maraviroc in atherosclerosis-prone mice and preliminary data in humans suggest an anti-atherosclerotic effect of the drug. The investigators assessed the impact of ma...
Eligibility Criteria
Inclusion
- Eligible patients were consecutive ≥50-year-old individuals, treated for over 1 year with an effective protease inhibitor ART regimen (HIV RNA \<50 copies/mL), with CD4 T cell counts \> 300/ mm3 for at least 6 months and a Framingham risk score \>20% and bFMD \<4%.
Exclusion
- Patients over 70 years of age, with life expectancy \< 12 months, with known platelets functional defects or alcohol chronic abuse were excluded.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2017
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT03402815
Start Date
January 1 2015
End Date
September 30 2017
Last Update
January 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Elisabetta Schiaroli
Perugia, Italy, 06126